New drug could cure malaria in one dose

New drug could cure malaria in one dose

6:06 AM, 1st April 2015
New drug could cure malaria in one dose
The new antimalarial drug - Triaminopyrimidine - comes with many advantages over existing drugs.

BENGALURU, INDIA: Three scientists from Bengaluru, India who led a team of global researchers looking for an antimalarial drug, have found a fast-killing solution. After completing some tests, it’ll go in for clinical trials on humans. This drug has the potential to cure the dreaded disease in one dose makes it more attractive to healthcare providers.

The solution — Triaminopyrimidine (TAP) — comes with many advantages over existing drugs. “It’s a fast-killing and long-acting antimalarial clinical candidate. TAP acts exclusively on the blood stage of Plasmodium falciparum (the stage responsible for clinical symptoms) in a relevant mouse model. This candidate is equally active against causative agent Plasmodium vivax. The compound has shown good safety margins in guinea pigs and rats. With a predicted half-life of 36 hours in humans, TAP offers potential for a single dose combination,” said Vasan Sambandamurthy, one of the senior authors of the research paper.

The rapid spread of Plasmodium falciparum, the parasite which causes malaria in humans, has left nations battling it with a weakened arsenal and coping with thousands of deaths every year. This parasite has gradually become resistant to available medication.

The World Health Organisation (WHO) estimates that 3.2 billion people in 97 countries, including India, are at risk of being infected with malaria. Every person infected with malaria has to deal with millions of parasites and existing drugs have a limited effect in humans. “The half-life, which isn’t more than 2 hours, means it allows parasites to bounce back. Existing drugs are not fast-killing, which means that not only does a human need more doses but each dose is capable of only killing a few parasites. Besides, a potential side-effect of existing drugs is liver damage. This doesn’t happen all the time, but the possibility does exist. Also, the parasites have become resistant to these drugs. With TAP, there are now known side-effects and the parasites are unable to develop resistance at the same pace as they do for existing drugs,” said Sambandamurthy.

TAP was discovered by a team at pharmaceutical company AstraZeneca. “The main research happened in its R&D centre in Bengaluru between 2011 and Fukuoka2014, which has since been shut down. It took us three years of rigorous work by teams across the globe. Today, we confidently nominate TAPs as a clinical candidate to treat drug-resistant malaria,” said Sambandamurthy. Shahul Hameed and Suresh Solapure were the two other team leaders.

The discovery of a malaria drug, yet again, highlights Bengaluru’s leadership in scientific research. The promise that the new medicine can kill the virus in a single stroke and act for a long time is good news for malaria patients. While the scientists deserve compliments on working towards a remedy free of side-effects, the companies that will eventually mass produce the drug should look at making it affordable to the common people.

 

© TimesOfIndia News 

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Converting carbon into renewable fuel

UMEA, SWEDEN: Earth-abundant materials based primarily on carbon, nitrogen and transition metal oxides can be combined into highly efficient energy co ...

Read more
Wrapping carbon nanotubes with polymer improves its performance

FUKUOKA, JAPAN: Scientists at Japan’s Kyushu University said polymer-wrapped carbon nanotubes hold much promise in biotechnology and energy appl ...

Read more
Dow to merge some operations with Olin

MIDLAND, US: The Dow Chemical Company and Olin Corporation announced today that the boards of directors of both companies unanimously approved a defin ...

Read more
LG Chem to expand TFT-LCD polarizer production in China

SEOUL, SOUTH KOREA: LG Chem, Korea’s largest chemical company, will invest $100 million to expand TFT-LCD polarizer production in Nanjing, China ...

Read more
Plant molecule could lead to eco-friendly roads

CAMBRIDGE, UK: A molecule that comes from plants and trees could lead to cheaper and more environmentally friendly roads and bike paths, according to ...

Read more
Efficient conversion of aldehydes into acids using silver

QUEBEC, CANADA: A tiny bit of silver, combined with water and air, can convert aldehydes into acids efficiently - instead of the classical methods usi ...

Read more